Show simple item record

FieldValueLanguage
dc.contributor.authorLipworth, W
dc.contributor.authorKerridge, I
dc.contributor.authorLittle, M
dc.contributor.authorDay, R
dc.date.accessioned2014-06-23
dc.date.available2014-06-23
dc.date.issued2012-01-01
dc.identifier.citationLipworth W, Kerridge I, Little JM, Day R. Evidence and desperation in off-label prescribing: recombinant factor VIIa. BMJ 2012;344:d7926en_AU
dc.identifier.otherhttp://211.144.68.84:9998/91keshi/Public/File/38/344-7840/pdf/bmj.d7926.full.pdf
dc.identifier.urihttp://hdl.handle.net/2123/10788
dc.description.abstractWendy Lipworth and colleagues explore why clinicians prescribe recombinant f actor VIIa off-label for major haemorrhage, despite a lack of supporting evidence—and why this mattersen_AU
dc.language.isoen_AUen_AU
dc.publisherBMJen_AU
dc.rightsCreative Commons Attribution Licence CC BY-NC 3.0en_AU
dc.titleEvidence and desperation in off-label prescribing: recombinant factor VIIaen_AU
dc.typeArticleen_AU


Show simple item record

Associated file/s

Associated collections

Show simple item record

There are no previous versions of the item available.